US 12,233,101 B2
Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and other diseases or symptoms
Emilie Annie Claudie Fromentin, Brain sur L'authion (FR); Douglas Andrew Klaiber, Forestdale, MA (US); and Daniel David Souza, East Sandwich, MA (US)
Assigned to Naturex Inc., South Hackensack, NJ (US)
Filed by NATUREX Inc., South Hackensack, NJ (US)
Filed on Feb. 28, 2022, as Appl. No. 17/682,190.
Application 16/661,749 is a division of application No. 16/532,367, filed on Aug. 5, 2019, granted, now 10,898,534, issued on Jan. 26, 2021.
Application 16/532,367 is a division of application No. 15/979,265, filed on May 14, 2018, granted, now 11,045,511, issued on Jun. 29, 2021.
Application 17/682,190 is a continuation of application No. 16/661,749, filed on Oct. 23, 2019, granted, now 11,291,703.
Application 15/979,265 is a continuation of application No. 15/150,722, filed on May 10, 2016, abandoned.
Application 15/150,722 is a continuation of application No. PCT/US2014/064961, filed on Nov. 11, 2014.
Claims priority of provisional application 61/902,376, filed on Nov. 11, 2013.
Prior Publication US 2022/0175863 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/45 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/09 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/34 (2006.01); A61K 31/341 (2006.01); A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61K 31/7048 (2006.01)
CPC A61K 36/45 (2013.01) [A61K 9/0053 (2013.01); A61K 9/16 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 9/4875 (2013.01); A61K 31/09 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/34 (2013.01); A61K 31/341 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/7048 (2013.01)] 16 Claims
 
1. A therapeutic composition comprising dried cranberry powder and dried cranberry seeds or cranberry seed meal,
wherein the cranberry seeds are present in an amount of about 5% to about 50% by weight of the dried cranberry powder, and
wherein the therapeutic composition is in a solid oral dosage form selected from the group consisting of a tablet, a capsule, a softgel, a gelcap, a caplet, a powder, a granule and a lozenge.